期刊文献+

大鼠重症急性胰腺炎时免疫机制及TAI的影响 被引量:3

下载PDF
导出
摘要 目的:研究重症急性胰腺炎(SAP)时细胞免疫功能的变化并通过给予外源性胸腺素α1(TA1),观察能否减轻SAP的严重程度并初步探讨其作用机制. 方法:♂SD大鼠54只随机分为对照组、SAP组和TA1治疗组.SAP模型采用50g/L牛黄胆酸钠1mL/kg胰胆管逆行穿刺注射建立,治疗组造模成功后立即皮下注射TA1 (100μg/kg),对照组仅给予开腹手术.三组大鼠分别在造模后3,6,12h处死,收集外周血与胰腺标本.观察TA1 对血清淀粉酶、TNF-α及胰腺组织炎症评分的影响;同时应用流式细胞术观察外周血CD3,CD4+,CD8+T细胞的变化. 结果:SAP组与治疗组各时间点血清淀粉酶、TNF-α水平及胰腺组织炎症评分均显著高于对照组(P<0.01):12 h治疗组与SAP组相比,TNF-α水平明显下降,胰腺组织炎症评分显著改善(P<0.01).SAP组3,6h外周血CD3, CD4+T细胞百分率较对照组明显升高(P<0.01);但在12h 则明显低于对照组(P<0.01);治疗组3 h外周血CD3, CD4+T细胞百分率较对照组明显升高(P<0.01),但6,12 h 与对照组没有明显的差异. 结论:SAP时存在细胞免疫功能的低下,外源性TA1可能通过调节CD3,CD4T细胞分化从而减轻胰腺炎症.
出处 《世界华人消化杂志》 CAS 2004年第9期2214-2216,共3页 World Chinese Journal of Digestology
基金 上海市自然科学基金资助.No.01ZB14026
  • 相关文献

参考文献15

  • 1Bhatnagar A, Wig JD, Majumdar S. Immunological findings in acute and chronic pancreatitis. ANZ J Surg 2003;73:59-64. 被引量:1
  • 2Pavlov P, Uchikov P,Murdzheva M, Tuleva-S, Tsvetkova T.Main lymphocyte populations and their subpopulations in patients with acute pancreatitis studied in the course of disease. Khirurgiia (Sofiia) 2001;57:4-11. 被引量:1
  • 3Kylanpaa-Back-ML, Takala A, Kemppainen E, Puolakkainen P, Kautiainen H, Jansson SE, Haapiainen R, Repo H. Cellular markers of systemic inflammation and immune suppression in patients with organ failure due to severe acute pancreatitis. Scand J Gastroenterol 2001;36:1100-1107. 被引量:1
  • 4Schmidt J, Rattner DW, Lewandrowski K, Compton CC,Mandavilli U, Knoefel WT, Warshaw AL. A better model of acute Pancreatitis for evaluating therapy. Ann Surg 1992;215:44-56. 被引量:1
  • 5Billich A. Thymosin alpha1. SciClone pharmaceuticals. Curr Opin Investig Drugs 2002;3:698-707. 被引量:1
  • 6Ancell CD, P-hipps-J, Young L. Thymosin alpha-1. Am J Health Syst Pharm 2001;58:879-885. 被引量:1
  • 7Ohmori H, Kamo M, Yamakoshi K, Nitta MH, Hikida M,Kanayama N. Restoration of immunocyte functions by thymosin alpha1 in cyclophosphamide-induced immunodeficient mice. Immunopharmacol Immunotoxicol 2001;23:75-82. 被引量:1
  • 8Garaci E, Pica F, Sinibaldi-Vallebona P, Pierimarchi P, Mastino A, Matteucci C, Rasi G. Thymosin alpha(1) in combination with cytokines and chemotherapy for the treatment of cancer.Int Immunopharmacol 2003;3:1145-1150. 被引量:1
  • 9Hugle T, Cerny A. Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C.Rev Med Virol 2003;13:361-371. 被引量:1
  • 10Andreone P, Gramenzi A, Cursaro C, Felline F, Loggi E,D'Errico A, Spinosa M, Lorenzini S, Biselli M, Bernardi M.Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C- results of a randomized controlled pilot trial. J Viral Hepat 2004;11:69-73. 被引量:1

同被引文献33

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部